Pharmacokinetics of Remifentanil: a three-compartmental modeling approach
暂无分享,去创建一个
Ornella Piazza | Gaetano Lamberti | Sara Cascone | Giuseppe Titomanlio | G. Titomanlio | G. Lamberti | S. Cascone | O. Piazza
[1] P. Glass,et al. Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra‐Short‐Acting Opioid: Remifentanil (GI87084B) , 1993, Anesthesia and analgesia.
[2] P. Glass,et al. Measured Context‐sensitive Half‐times of Remifentanil and Alfentanil , 1995, Anesthesiology.
[3] K T Muir,et al. Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient Surgery , 1993, Anesthesiology.
[4] K T Muir,et al. Pharmacokinetics and Pharmacodynamics of Remifentanil in Volunteer Subjects with Severe Liver Disease , 1996, Anesthesiology.
[5] G. Titomanlio,et al. The influence of dissolution conditions on the drug ADME phenomena. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[6] David J. Hermann,et al. The Pharmacokinetics of the New Short‐acting Opioid Remifentanil (GI87084B) in Healthy Adult Male Volunteers , 1993, Anesthesiology.
[7] Gaetano Lamberti,et al. Modeling the pharmacokinetics of extended release pharmaceutical systems , 2009 .
[8] H. Akaike. A new look at the statistical model identification , 1974 .